SUNLIGHT

NCT04737187 📎

Regimen

Experimental
Trifluridine/tipiracil (TAS-102) + bevacizumab
Control
Trifluridine/tipiracil (TAS-102) alone

Population

Metastatic CRC, 3L+ (≤2 prior lines of therapy for metastatic disease), refractory to standard therapy; unselected by biomarker.

Key finding

3L+ refractory mCRC (≤2 prior chemo regimens): mOS FTD-TPI+bev 10.8 vs FTD-TPI 7.5 mo (HR 0.61, 95% CI 0.49-0.77, p<0.001); mPFS 5.6 vs 2.4 mo (HR 0.44, 95% CI 0.36-0.54, p<0.001); time to PS deterioration 9.3 vs 6.3 mo (HR 0.54); no treatment-related deaths; primary OS endpoint met

Source: PMID 37133585

Timeline

    Guideline citations

    • NCCN Colon (p.155)